Literature DB >> 27378428

MLF1IP is correlated with progression and prognosis in luminal breast cancer.

Du-Ping Huang1, Rong-Cheng Luo2.   

Abstract

Myeloid leukemia factor 1-interacting protein (MLF1IP) has been found to be involved in the progression of several malignancies. The potential correlation between MLF1IP and clinical outcome in patients with luminal breast cancer, however, remains unknown. In the present study, we demonstrated that MLF1IP was significantly upregulated in luminal breast cancer tissue compared with adjacent normal tissue both in validated cohort and TCGA cohort. Upregulated expression of MLF1IP was correlated with more often lymph node metastasis and negative progesterone receptor expression in TCGA cohorts. Kaplan-Meier analysis indicated that patients with high MLF1IP expression had significantly lower overall survival. Moreover, multivariate analysis revealed that high MLF1IP expression was independent high risk factor as well as old age (>60) and distant metastasis. This study provides new insights and evidences that MLF1IP over-expression plays important roles in progression of luminal breast cancer. However, the precise cellular mechanisms for MLF1IP in luminal breast cancer need to be further explored.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Luminal breast cancer; MLF1IP; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27378428     DOI: 10.1016/j.bbrc.2016.06.159

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.

Authors:  Hongjuan Li; Hui Zhang; Yali Wang
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  The effect of centromere protein U silencing by lentiviral mediated RNA interference on the proliferation and apoptosis of breast cancer.

Authors:  Shuang-Yan Lin; Yan-Bo Lv; Gen-Xiang Mao; Xu-Jiao Chen; Fang Peng
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

3.  Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.

Authors:  Lei Liu; Yayun Chi; Jiajian Chen; Jingyan Xue; Linlin Deng; Naisi Huang; Jianghua Shao; Jiong Wu
Journal:  Sci Rep       Date:  2017-09-28       Impact factor: 4.379

4.  Centromere protein U expression promotes non-small-cell lung cancer cell proliferation through FOXM1 and predicts poor survival.

Authors:  Xinxin Wang; Diangang Chen; Jianbao Gao; Haixia Long; Haoran Zha; Anmei Zhang; Chi Shu; Li Zhou; Fei Yang; Bo Zhu; Wei Wu
Journal:  Cancer Manag Res       Date:  2018-12-14       Impact factor: 3.989

5.  Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma.

Authors:  Ying-Jian Song; Juan Tan; Xin-Huai Gao; Li-Xin Wang
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

6.  Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer.

Authors:  Minhua Wu; Jinhua Ding; Limu Wen; Yuxin Zhou; Weizhu Wu
Journal:  Biomed Res Int       Date:  2021-03-16       Impact factor: 3.411

7.  Identification of Key Biomarkers and Pathways in Small-Cell Lung Cancer Using Biological Analysis.

Authors:  Huanqing Liu; Tingting Li; Xunda Ye; Jun Lyu
Journal:  Biomed Res Int       Date:  2021-10-19       Impact factor: 3.411

8.  Comprehensive Analysis of the Expression and Prognostic Significance of the CENP Family in Breast Cancer.

Authors:  Xueliang Liu; Yunjiang Liu
Journal:  Int J Gen Med       Date:  2022-03-29

9.  Centromere protein U is a potential target for gene therapy of human bladder cancer.

Authors:  Sheng Wang; Beibei Liu; Jiajun Zhang; Wei Sun; Changyuan Dai; Wenyan Sun; Qingwen Li
Journal:  Oncol Rep       Date:  2017-06-30       Impact factor: 3.906

10.  Identification of CDCA8, DSN1 and BIRC5 in Regulating Cell Cycle and Apoptosis in Osteosarcoma Using Bioinformatics and Cell Biology.

Authors:  Qinwen Li; Jie Liang; Bo Chen
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.